Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment with platelet-derived growth factor in pigs in vivo

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 4, 1997, Pages 536-545

  Kozai, Toshiyuki ^a   Shimokawa, Hiroaki ^a   Fukumoto, Yoshihiro ^a   Kobayashi, Sei ^a   Owada, M Koji ^b   Kadokami, Toshiaki ^a   Ito, Akira ^a   Kuwata, Kouichi ^a   Egashira, Kensuke ^a   Shiraishi, Tadayoshi ^c   Kanaide, Hideo ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c KANEKA CORPORATION   (Japan)

Author keywords

Coronary vasospasm; Platelet derived growth factor; Restenosis; Tyrosine kinases; Vascular remodeling

Indexed keywords

ALPHA CYANO 3 ETHOXY 4 HYDROXY 5 (PHENYLTHIOMETHYL)CINNAMAMIDE; HISTAMINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DRUG EFFECT; HISTOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL;

ABSORPTION; ANALYSIS OF VARIANCE; ANGIOGRAPHY; ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL AVAILABILITY; CINNAMATES; CORONARY VASOSPASM; CORONARY VESSELS; HUMANS; IMMUNOBLOTTING; MALE; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; SULFIDES; SWINE;

EID: 0030970339     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199704000-00016     Document Type: Article

References (34)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Munro JM, Cotran RS. Biology of disease. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988;58:249-61.
3. Hannson GK, Jonasson L, Seifert PS, Stemme S. Immune mechannisms in atherosclerosis. Arteriosclerosis 1989;9:567-78.
4. Shimokawa H, Tomoike H, Nabeyama S, et al. Coronary artery spasm induced in atherosclerotic miniature swine. Science 1983;221:560-2.
5. Shimokawa H, Tomoike H, Nabeyama S, et al. Coronary artery spasm induced in miniature swine: angiographic evidence and relation to coronary atherosclerosis. Am Heart J 1985;110:300-10.
6. Egashira K, Tomoike H, Yamamoto Y, Yamada A, Hayashi Y, Nakamura M. Histamine-induced coronary spasm in regions of intimal thickening in miniature pigs: roles of serum cholesterol and spontaneous or induced intimal thickening. Circulation 1986;74:826-37.
7. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 1974;71:1207-10.
8. Grotendorst GR, Chang T, Seppa HEJ, Kleinman HK, Martin GR. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol 1982;113:261-6.
9. Ferns GAA, Rains EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-32.
10. Nabel EG, Yang Z, Liptay S, et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993;91:1822-9.
11. Wang JYJ, McWhiter JR. Tyrosme kinase-dependent signaling pathways. Trends Cardiovasc Med 1994;4:264-70.
12. Helden CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1990;1:555-66.
13. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor. J Clin Invest 1996;97:769-76.
14. Ito A, Shimokawa H, Kadokami T, et al. Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1β in pigs in vivo. J Clin Invest 1995;96:1288-94.
15. Shiraishi T, Domoto T, Imai N, Shimada Y, Watanahe K. Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Bilophys Res Commun 1987;147:322-8.
16. Shiraishi T, Owada MK, Tatsuka M, Yamashita T, Watanabe K, Kakunaga T. Specific inhibitor of tyrosine-specific protein kinases: properties of 4-hydroxycinnamamide derivatives in vitro. Cancer Res 1987;49:2374-8.
17. Kita M, Ohmoto Y, Hirai Y, Yamaguchi N, Imanishi J. Induction of cytokines in human peripheral blood mononuclear cells by mycoplasmas. Microbiol Immunol 1992;36:507-16.
18. DiMario C, Gil R, Camenzind E, et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol 1995;75:772-7.
19. Andersen HR, Mæng M, Thorwest M, Falk E. Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury; insights from a porcine coronary (re)stenosis model. Circulation 1996;93:1716-24.
20. Pasterkamp G, Wensing PJW, Post MJ, Hillen B, Mali WPTM, Borst C. Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries. Circulation 1995;91:1444-9.
21. Owada MK, Iwamoto M, Koike T, Kato Y. Effects of vanadate on tyrosine phosphorylation and the pattern of polycoaminoglycan synthesis in rabbit chondrocytes in culture. J Cell Physiol 1989;138:484-92.
22. Hosang M, Rouge M, Wipf R, Eggimann B, Kaufmann F, Hunziker W. Both homodimeric isoforms of PDGF (AA and BB) have mitogenic and chemotactic activity and stimulate phosphoinositol turnover. J Cell Physiol 1989;140:558-64.
23. Siegbahn A, Hammacher A, Westermark B, Heldin CH. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990;85:916-20.
24. Scott NA, Cipolla GD, Ross CE, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996;93:2178-87.
25. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science 1986;232:87-90.
26. Ogawa H, Yasue H, Okumura K, et al. Platelet-derived growth factor is released into the coronary circulation after coronary spasm, Coron Artery Dis 1993;4:437-42.
27. Ito A, Shimokawa H, Nakaike R, et al. Role of protein kinase C-mediated pathway in the pathogenesis of coronary artery spasm in a swine model. Circulation 1994;90:2425-31.
28. Kadokami T, Shimokawa H, Fukumoto Y, et al. Coronary artery spasm does not depend on the intracellular calcium store but is substantially mediated by the protein kinase C-mediated pathway in a swine model with interleukin-1β in vivo. Circulation 1996;94: 19-06.
29. Fukumoto Y, Shimokawa H, Kozai T, et al. Tyrosine kinase inhibitor suppresses the (re)stenotic changes of the coronary artery after balloon injury in pigs. Cardiovasc Res 1996;32:1131-40.
30. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Medelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 1983;80:1337-41.
31. Ito A, Shimokawa H, Fukumoto Y, et al. The role of fibroblast growth factor-2 in the vascular effects of interleukin-1β in porcine coronary arteries in vivo. Cardiovasc Res 1996;32:570-9.
32. Di Salvo J, Steusloff A, Semenchuk L, Satoh S, Kolquist K, Pfitzer G. Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun 1993;190: 947-68.
33. Linder V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 1991;88:3739-43.
34. Grant MB, Wargovich TG, Ellis EA, Cabellero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment for restenosis? Circulation 1994;89:1511-7.